Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2009

KeyNeurotek Opens New Site in Germany

KeyNeurotek Opens New Site in Germany

KeyNeurotek opens new facility in Leipzig, Germany

  • KeyNeurotek Pharmaceuticals has opened new research facilities and office space in the BIO CITY center in Leipzig, Germany. It will advance preclinical activities and further clinical work in urinary incontinence as well as autoimmune diseases and neurodegenerative diseases.

    The firm will use the space to continue to prepare a Phase IIa study of its KN203 compound, a mu-opiod receptor agonist that acts on bladder muscle contraction. The clinical testing is expected to begin this year.

    This facility will also allow KeyNeurotek's original Magdeburg facility to expand its work on lead product KN38-7271, a traumatic brain injury treatment for the comatose that is being studied in a Phase IIa trial to test its cannabinoid CB1/CB2 receptor agonist mechanism.ADNFCR-2184-ID-19157705-ADNFCR



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »